Molecular Diagnostics Market Research Report
The clinical laboratory, molecular diagnostics has become indispensable. This includes all methods and tests for the identification of a disease and comprehending the predisposition for a disease by analyzing DNA or RNA of an organism. The rapid advances in molecular diagnostics have significantly enabled basic research and results in practical diagnosis.
The clinical laboratory, molecular diagnostics has become indispensable. This includes all methods and tests for the identification of a disease and comprehending the predisposition for a disease by analyzing DNA or RNA of an organism. The rapid advances in molecular diagnostics have significantly enabled basic research and results in practical diagnosis.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Global <strong>Molecular</strong><br />
<strong>Diagnostics</strong> <strong>Market</strong><br />
Focus on Product Type (Kits and Consumables, Systems,<br />
Software & Others), Applications, Technologies, End-User,<br />
Country Data (15 Countries), and Competitive Landscape:<br />
Analysis and Forecast: 2018-2028<br />
Key Questions Answered in the <strong>Report</strong><br />
• What are the major market drivers, challenges, and opportunities in the global<br />
molecular diagnostics market?<br />
• What are the underlying structures resulting in the emerging trends within the<br />
global molecular diagnostics market?<br />
MORE THAN<br />
50+ COMPANIES<br />
RESEARCHED<br />
ACROSS THE VALUE<br />
CHAIN<br />
METICULOUS<br />
COMPILATION OF<br />
MORE THAN 700<br />
RESEARCH HOURS<br />
EXCLUSIVE INSIGHTS<br />
FROM IN-DEPTH<br />
EXPERT INTERVIEWS<br />
CONTAINS 11<br />
MARKET DATA TABLES<br />
AND 218 FIGURES<br />
SPREAD ACROSS<br />
358 PAGES<br />
• How will each segment of the global molecular diagnostics market grow during<br />
the forecast period and what will be the revenue generated by each of the<br />
segments by the end of 2028?<br />
• What are the key developmental strategies which are implemented by the major<br />
players in order to sustain in the competitive market? What are the key regulatory<br />
implications in developed and developing regions for molecular diagnostics?<br />
• Who are the leading players with significant offerings to the global molecular<br />
diagnostics market? What is the current market dominance for each of these<br />
leading players?<br />
• What would be the compound growth rate witnessed by the leading players in the<br />
market during the forecast period 2018-2028? Which molecular diagnostic<br />
product type is having the most promising growth?<br />
• What are the key applications in global molecular diagnostics market? What are<br />
the major segments of these applications? What technologies are dominating<br />
these application segments?<br />
• What are the major technologies that are employed in the global molecular<br />
diagnostics market? Which is the dominating technology?<br />
• Who are the primary end-users of the global molecular diagnostics market?<br />
Which is the fastest growing end-use segment in the global molecular diagnostics<br />
market?<br />
• Who are the key manufacturers in the global molecular diagnostics market, and<br />
what are their contributions? Also, what is the growth potential of each major<br />
molecular diagnostics manufacturer?<br />
• What is the scope of the global molecular diagnostics market in North America,<br />
Europe, Asia-Pacific, Latin America, and Rest-of-the-World? Which molecular<br />
diagnostics application dominates these regions?<br />
sales@bisresearch.com | www.bisresearch.com
Table of Contents<br />
MARKET OVERVIEW<br />
MARKET DYNAMICS<br />
COMPETITIVE LANDSCAPE<br />
REGULATORY FRAMEWORK<br />
GLOBAL MOLECULAR<br />
DIAGNOSTICS MARKET<br />
(BY PRODUCT)<br />
GLOBAL MOLECULAR<br />
DIAGNOSTICS MARKET<br />
(BY APPLICATION)<br />
GLOBAL MOLECULAR<br />
DIAGNOSTICS MARKET<br />
(BY TECHNOLOGY)<br />
GLOBAL MOLECULAR<br />
DIAGNOSTICS MARKET<br />
(BY END-USER)<br />
GLOBAL MOLECULAR<br />
DIAGNOSTICS MARKET<br />
(BY END-USER)<br />
• Introduction<br />
• <strong>Market</strong> Definition<br />
• Historical Perspective<br />
• Significant Technologies<br />
• Classification of <strong>Molecular</strong> <strong>Diagnostics</strong><br />
• Global Footprint<br />
• Future Potential<br />
• Overview<br />
• Iceberg Analysis – Global <strong>Molecular</strong><br />
<strong>Diagnostics</strong> <strong>Market</strong><br />
• Impact Analysis<br />
• <strong>Market</strong> Drivers<br />
• <strong>Market</strong> Restraints<br />
• Opportunities<br />
• Key Strategies and Developments<br />
• <strong>Market</strong> Share Analysis<br />
• Growth Share Analysis (Opportunity<br />
Mapping)<br />
• Industry Attractiveness<br />
• Legal Requirements and Framework in<br />
the U.S.<br />
• Legal Requirements and Framework in<br />
Europe<br />
• Legal Requirements and Framework in<br />
Asia-Pacific<br />
• Overview<br />
• Kits and Consumables<br />
• Systems<br />
• Software and Other Products<br />
• Overview<br />
• Core <strong>Molecular</strong> <strong>Diagnostics</strong><br />
• Non-Invasive Prenatal Testing (NIPT)<br />
• Companion <strong>Diagnostics</strong> (CDx)<br />
• Liquid Biopsy<br />
• Others<br />
• Overview<br />
• Polymerase Chain Reaction (PCR)<br />
• Sequencing<br />
• Microarray<br />
• In-situ Hybridization (ISH)<br />
• Immunohistochemistry (IHC)<br />
• Nucleic Acid Amplification<br />
• Isothermal Amplification<br />
• Others<br />
• Overview<br />
• Hospitals<br />
• Diagnostic Centers<br />
• Out-Patient Clinics/General Practitioners<br />
• <strong>Research</strong> Laboratories<br />
• Overview<br />
• Hospitals<br />
• Diagnostic Centers<br />
• Out-Patient Clinics/General Practitioners<br />
• <strong>Research</strong> Laboratories<br />
SCOPE &<br />
RESEARCH<br />
METHODOLOGY<br />
• <strong>Report</strong> Scope<br />
• Human <strong>Molecular</strong><br />
<strong>Diagnostics</strong> <strong>Market</strong>:<br />
<strong>Research</strong> Methodology<br />
COMPANY<br />
PROFILES<br />
• Overview<br />
• Abbott Laboratories<br />
• Agilent Technologies, Inc.<br />
• Becton, Dickinson and<br />
Company<br />
• bioMérieux S.A.<br />
• Bio-Rad Laboratories,<br />
Inc.<br />
• Cynvenio Biosystems,<br />
Inc.<br />
• Danaher Corporation<br />
• F. Hoffmann-La Roche<br />
AG<br />
• GUARDANT HEALTH,<br />
INC<br />
• Illumina, Inc.<br />
• Invivoscribe<br />
Technologies, Inc.<br />
• <strong>Molecular</strong>MD Corporation<br />
• QIAGEN N.V.<br />
• Siemens Healthineers,<br />
Inc.<br />
• Thermo Fisher Scientific<br />
Inc.<br />
• QuantuMDx Group Ltd.<br />
• HTG <strong>Molecular</strong><br />
<strong>Diagnostics</strong>, Inc.<br />
VIEW COMPLETE TABLE OF CONTENT<br />
sales@bisresearch.com | www.bisresearch.com
List of Tables<br />
1. Impact Analysis of <strong>Market</strong> Drivers<br />
2. Impact Analysis of <strong>Market</strong> Restraints<br />
3. Classification rules of IVDs under the IVDR<br />
4. Registration Criteria for IVD Medical Devices as<br />
per the CFDA<br />
5. Genetic Tests for Certain Applications<br />
6. Examples of <strong>Molecular</strong> <strong>Diagnostics</strong> in Cancer<br />
7. North America <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by<br />
Application), 2017-2028<br />
8. Europe <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by<br />
Application), 2017-2028<br />
9. APAC <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by<br />
Application), 2017-2028<br />
10. Latin America <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by<br />
Application), 2017-2028<br />
11. RoW <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by<br />
Application), 2017-2028<br />
List of Figures<br />
1. Global Precision Medicine <strong>Market</strong>, 2016 and 2020<br />
2. Impact of <strong>Market</strong> Drivers and <strong>Market</strong> Restraints on<br />
the Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong><br />
3. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> Snapshot<br />
4. Dominating Segments of the Global <strong>Molecular</strong><br />
<strong>Diagnostics</strong> <strong>Market</strong>, 2017 and 2028<br />
5. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Product),<br />
2017 and 2028<br />
6. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Product),<br />
2017<br />
7. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Product),<br />
2028<br />
8. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by<br />
Technology), 2017 and 2028<br />
9. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by<br />
Technology), 2017 and 2028<br />
10. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by<br />
Technology), 2017 and 2028<br />
11. Role of <strong>Diagnostics</strong> in Healthcare<br />
12. Evolution of <strong>Molecular</strong> <strong>Diagnostics</strong><br />
13. Classification of <strong>Molecular</strong> <strong>Diagnostics</strong><br />
14. Global <strong>Molecular</strong> <strong>Diagnostics</strong> (MDx) <strong>Market</strong>, 2017-<br />
2028<br />
15. Iceberg Analysis - Global <strong>Molecular</strong> <strong>Diagnostics</strong><br />
<strong>Market</strong><br />
16. Number of Deaths by Top 18 Infectious Diseases,<br />
2015<br />
17. Strategies to Integrate Personalized Medicine for<br />
Routine Healthcare Procedures<br />
18. Benefits of Multiplexing Reactions<br />
19. Share of Key Developments and Strategies, January<br />
2016 - December 2018<br />
20. Synergistic Activities Share (by Companies), January<br />
2016 - December 2018<br />
21. Approvals Share (by Companies), January 2016 -<br />
December 2018<br />
22. Product Launches and Enhancements Share (by<br />
Companies), January 2016 - December 2018<br />
23. Acquisitions Share (by Companies), January 2016 -<br />
December 2018<br />
sales@bisresearch.com | www.bisresearch.com
List of Figures<br />
24. <strong>Market</strong> Share Analysis for the Global <strong>Molecular</strong><br />
<strong>Diagnostics</strong> <strong>Market</strong>, 2016<br />
25. <strong>Market</strong> Share Analysis for the Global <strong>Molecular</strong><br />
<strong>Diagnostics</strong> <strong>Market</strong>, 2017<br />
26. Growth Share Matrix (Opportunity Mapping Matrix)<br />
for Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by<br />
companies), 2016<br />
27. Growth Share Matrix (Opportunity Mapping Matrix)<br />
for Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by<br />
companies), 2017<br />
28. Overall Industry Attractiveness, 2018 and 2028<br />
29. Overall Impact of Bargaining Power of Suppliers<br />
30. Overall Impact of Bargaining Power of Buyers<br />
31. Overall Impact of Threat of New Entrants<br />
32. Overall Impact of Threat of Substitute Products<br />
33. Overall Impact of Intensity of Competitive Rivalry<br />
34. Components Considered for Clinical Evidence as<br />
per the IVDR<br />
35. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Product)<br />
36. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Product),<br />
2017 and 2028<br />
37. General Workflow of a <strong>Molecular</strong> Diagnostic Kit<br />
38. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Kits and<br />
Consumables), 2017-2028<br />
39. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Systems),<br />
2017-2028<br />
40. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Systems,<br />
by Type), 2017-2028<br />
41. Aspects of Software Development<br />
42. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Software<br />
and Other Products), 2017-2028<br />
43. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Application)<br />
44. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by<br />
Application), 2017<br />
45. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by<br />
Application), 2028<br />
46. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Core MDx<br />
Applications), 2017 and 2028<br />
47. Nucleic Acid Testing Techniques for Infectious<br />
Diseases<br />
48. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Infectious<br />
Diseases), 2017-2028<br />
49. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Infectious<br />
Diseases), 2017 and 2028<br />
50. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Infectious<br />
Diseases, by Technology), 2017 and 2028<br />
51. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Genetic<br />
Testing), 2017-2028<br />
52. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Genetic<br />
Testing, by Technology), 2017 and 2028<br />
53. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Blood<br />
Donor Screening), 2017-2028<br />
54. Clinical Uses of <strong>Molecular</strong> <strong>Diagnostics</strong> in Cancer<br />
55. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Cancer),<br />
2017-2028<br />
56. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Oncology),<br />
2017 and 2028<br />
57. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Oncology,<br />
by Technology), 2017 and 2028<br />
58. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by HLA<br />
Testing), 2017-2028<br />
59. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Other<br />
Applications), 2017-2028<br />
60. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Companion<br />
<strong>Diagnostics</strong>), 2017 and 2028<br />
61. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by NIPT, by<br />
Technology), 2017 and 2028<br />
62. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Companion<br />
<strong>Diagnostics</strong>), 2017 and 2028<br />
63. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Companion<br />
<strong>Diagnostics</strong>, by Technology), 2017 and 2028<br />
64. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Liquid<br />
Biopsy), 2017 and 2028<br />
65. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Liquid<br />
Biopsy, by Technology), 2017 and 2028<br />
66. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by<br />
Technology)<br />
67. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by<br />
Technology), 2017<br />
68. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by PCR),<br />
2017-2028<br />
sales@bisresearch.com | www.bisresearch.com
List of Figures<br />
69. Evolution of Sequencing for <strong>Molecular</strong> <strong>Diagnostics</strong><br />
70. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by<br />
Sequencing), 2017-2028<br />
71. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by<br />
Microarray), 2017-2028<br />
72. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by ISH),<br />
2017-2028<br />
73. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by IHC),<br />
2017-2028<br />
74. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by NAA),<br />
2017-2028<br />
75. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Isothermal<br />
Amplification), 2017-2028<br />
76. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Other<br />
Technologies), 2017-2028<br />
77. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by End-User)<br />
78. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by End-User),<br />
2017 and 2028<br />
79. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Hospitals),<br />
2017-2028<br />
80. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Diagnostic<br />
Centers), 2017-2028<br />
81. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Out-Patient<br />
Clinics/GPs), 2017-2028<br />
82. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by <strong>Research</strong><br />
Laboratories), 2017-2028<br />
83. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Region),<br />
2017 and 2028<br />
84. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Region),<br />
2017-2028<br />
85. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> Share (by<br />
Region), 2017<br />
86. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> Share (by<br />
Region), 2028<br />
87. North America <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong>, 2017-<br />
2028<br />
88. North America: <strong>Market</strong> Dynamics<br />
89. North America <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by<br />
Country), 2017-2028<br />
90. The U.S. <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong>, 2017-2028<br />
91. Canada <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong>, 2017-2028<br />
92. Overview of Reimbursement Policies in Europe<br />
(Focus on Companion <strong>Diagnostics</strong> as well)<br />
93. Europe <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong>, 2017-2028<br />
94. Europe: <strong>Market</strong> Dynamics<br />
95. Europe <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Country),<br />
2017-2028<br />
96. Germany <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong>, 2017-2028<br />
97. France <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong>, 2017-2028<br />
98. Italy <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong>, 2017-2028<br />
99. The U.K. <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong>, 2017-2028<br />
100. Spain <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong>, 2017-2028<br />
101. The Netherlands <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong>,<br />
2017-2028<br />
102. Rest-of-Europe <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong>, 2017-<br />
2028<br />
103. Asia-Pacific <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong>, 2017-<br />
2028<br />
104. APAC: <strong>Market</strong> Dynamics<br />
105. APAC <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by Country),<br />
2017-2028<br />
106. Japan <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong>, 2017-2028<br />
107. China <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong>, 2017-2028<br />
108. India <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong>, 2017-2028<br />
109. Australia <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong>, 2017-2028<br />
110. Singapore <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong>, 2017-2028<br />
111. RoAPAC <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong>, 2017-2028<br />
112. Latin America <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong>, 2017-<br />
2028<br />
113. Latin America: <strong>Market</strong> Dynamics<br />
114. Latin America <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> (by<br />
Country), 2017-2028<br />
115. Brazil <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong>, 2017-2028<br />
116. Mexico <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong>, 2017-2028<br />
117. Rest-of-Latin America <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong>,<br />
2017-2028<br />
118. RoW <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong>, 2017-2028<br />
sales@bisresearch.com | www.bisresearch.com
List of Figures<br />
119. Total Number of Companies Profiled<br />
120. Abbott Laboratories: Overall Product Portfolio<br />
121. Abbott Laboratories: Overall Financials, 2015-2017<br />
122. Abbott Laboratories: Revenue (by Segment), 2015-<br />
2017<br />
123. Abbott Laboratories: Revenue Split for <strong>Diagnostics</strong>,<br />
2015-2017<br />
124. Abbott Laboratories: Revenue (by Region), 2015-<br />
2017<br />
125. Abbott Laboratories: R&D Expenditure, 2015-2017<br />
126. Abbott Laboratories: Revenue Forecast, 2015-2020<br />
127. Abbott Laboratories: SWOT Analysis<br />
128. Agilent Technologies, Inc.: Overall Product Portfolio<br />
129. Agilent Technologies, Inc.: Overall Financials, 2015-<br />
2017<br />
130. Agilent Technologies, Inc.: Revenue (by Segment),<br />
2015-2017<br />
131. Agilent Technologies, Inc.: Revenue (by Region),<br />
2015-2017<br />
132. Agilent Technologies, Inc.: R&D Expenditure, 2015-<br />
2017<br />
133. Agilent Technologies, Inc.: Revenue Forecast, 2015-<br />
2020<br />
134. Agilent Technologies, Inc.: SWOT Analysis<br />
135. Becton, Dickinson and Company: Overall Product<br />
Portfolio<br />
136. Becton, Dickinson and Company: Overall Financials,<br />
2015-2017<br />
137. Becton, Dickinson and Company: Revenue (by<br />
Segment), 2015-2017<br />
138. Becton, Dickinson and Company: Revenue Split for<br />
BD Life Sciences, 2015-2017<br />
139. Becton, Dickinson and Company: Revenue (by<br />
Region), 2015-2017<br />
140. Becton, Dickinson and Company: R&D Expenditure,<br />
2015-2017<br />
141. Becton, Dickinson and Company: Revenue<br />
Forecast, 2015-2020<br />
142. Becton, Dickinson and Company: SWOT Analysis<br />
143. bioMérieux S.A.: Overall Product Portfolio<br />
144. bioMérieux S.A.: Overall Financials, 2015-2017<br />
145. bioMérieux S.A.: Revenue (by Segment), 2015-2017<br />
146. bioMérieux S.A.: Revenue (by Region), 2015-2017<br />
147. bioMérieux S.A.: R&D Expenditure, 2015-2017<br />
148. bioMérieux S.A.: Revenue Forecast, 2015-2020<br />
149. bioMérieux S.A.: SWOT Analysis<br />
150. Bio-Rad Laboratories, Inc.: Overall Product Portfolio<br />
151. Bio-Rad Laboratories, Inc.: Overall Financials, 2015-<br />
2017<br />
152. Bio-Rad Laboratories, Inc.: Revenue (by Segment),<br />
2015-2017<br />
153. Bio-Rad Laboratories, Inc.: Revenue (by Region),<br />
2015-2017<br />
154. Bio-Rad Laboratories, Inc.: R&D Expenditure, 2015-<br />
2017<br />
155. Bio-Rad Laboratories, Inc.: SWOT Analysis<br />
156. Cynvenio Biosystems, Inc.: Overall Product Portfolio<br />
157. Cynvenio Biosystems, Inc.: SWOT Analysis<br />
158. Danaher Corporation: Overall Product Portfolio<br />
159. Danaher Corporation: Overall Financials, 2015-2017<br />
160. Danaher Corporation: Revenue (by Segment), 2015-<br />
2017<br />
161. Danaher Corporation: Revenue Split for <strong>Diagnostics</strong>,<br />
2015-2017<br />
162. Danaher Corporation: Revenue (by Region), 2015-<br />
2017<br />
163. Danaher Corporation: R&D Expenditure, 2015-2017<br />
164. Danaher Corporation: Revenue Forecast, 2015-2020<br />
165. Danaher Corporation: SWOT Analysis<br />
166. F. Hoffmann-La Roche AG: Overall Product Portfolio<br />
167. F. Hoffmann-La Roche AG: Overall Financials, 2015-<br />
2017<br />
168. F. Hoffmann-La Roche AG: Revenue (by Segment),<br />
2015-2017<br />
169. F. Hoffmann-La Roche AG: Revenue Split for<br />
<strong>Diagnostics</strong>, 2015-2017<br />
170. F. Hoffmann-La Roche AG: Revenue (by Region),<br />
sales@bisresearch.com | www.bisresearch.com
List of Figures<br />
2015-2017<br />
171. F. Hoffmann-La Roche AG: R&D Expenditure,<br />
2015-2017<br />
172. F. Hoffmann-La Roche AG: Revenue Forecast,<br />
2015-2020<br />
173. F. Hoffmann-La Roche AG: SWOT Analysis<br />
174. GUARDANT HEALTH, INC: Overall Product<br />
Portfolio<br />
175. GUARDANT HEALTH, INC: SWOT Analysis<br />
176. Illumina, Inc.: Overall Product Portfolio<br />
177. Illumina, Inc.: Overall Financials, 2015-2017<br />
178. Illumina, Inc.: Revenue (by Segment), 2015-2017<br />
179. Illumina, Inc.: Revenue (by Region), 2015-2017<br />
180. Illumina, Inc.: R&D Expenditure, 2015-2017<br />
181. Illumina, Inc.: Revenue Forecast, 2015-2020<br />
182. Illumina, Inc.: SWOT Analysis<br />
183. Invivoscribe Technologies, Inc.: Overall Product<br />
Portfolio<br />
184. Invivoscribe Technologies, Inc.: SWOT Analysis<br />
185. <strong>Molecular</strong>MD Corporation: Overall Product<br />
Portfolio<br />
186. <strong>Molecular</strong>MD Corporation: SWOT Analysis<br />
187. QIAGEN N.V.: Overall Product Portfolio<br />
188. QIAGEN N.V.: Overall Financials, 2015-2017<br />
189. QIAGEN N.V.: Revenue (by Segment), 2015-2017<br />
190. QIAGEN N.V.: Revenue (by Region), 2015-2017<br />
191. QIAGEN N.V.: R&D Expenditure, 2015-2017<br />
192. QIAGEN N.V.: Revenue Forecast, 2015-2020<br />
193. QIAGEN N.V.: SWOT Analysis<br />
194. Siemens Healthineers, Inc.: Overall Product<br />
Portfolio<br />
195. Siemens Healthineers, Inc.: Overall Financials,<br />
2016-2018<br />
196. Siemens Healthineers, Inc.: Revenue (by<br />
Segment), 2016-2018<br />
197. Siemens Healthineers, Inc.: Revenue (by Region),<br />
2016-2018<br />
198. Siemens Healthineers, Inc.: R&D Expenditure,<br />
2016-2018<br />
199. Siemens Healthineers, Inc.: Revenue Forecast,<br />
2015-2020<br />
200. Siemens Healthineers, Inc.: SWOT Analysis<br />
201. Thermo Fisher Scientific Inc.: Overall Product<br />
Portfolio<br />
202. Thermo Fisher Scientific Inc.: Overall Financials,<br />
2015-2017<br />
203. Thermo Fisher Scientific Inc.: Revenue (by<br />
Segment), 2015-2017<br />
204. Thermo Fisher Scientific Inc.: Revenue (by<br />
Region), 2015-2017<br />
205. Thermo Fisher Scientific Inc.: R&D Expenditure,<br />
2015-2017<br />
206. Thermo Fisher Scientific Inc.: Revenue Forecast,<br />
2015-2020<br />
207. Thermo Fisher Scientific Inc.: SWOT Analysis<br />
208. QuantuMDx Group Ltd.: Overall Product Portfolio<br />
(Available from FY2019)<br />
209. HTG <strong>Molecular</strong> <strong>Diagnostics</strong>, Inc.: Overall Product<br />
Portfolio<br />
210. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong><br />
Segmentation<br />
211. Global <strong>Molecular</strong> <strong>Diagnostics</strong> <strong>Market</strong> <strong>Research</strong><br />
Methodology<br />
212. Primary <strong>Research</strong><br />
213. Secondary <strong>Research</strong><br />
214. Data Triangulation<br />
215. Bottom-up Approach (Segment-wise Analysis)<br />
216. Top-down Approach (Segment-wise Analysis)<br />
217. Assumptions and Limitations<br />
218. Considered Factors for Data Prediction and<br />
Modeling<br />
sales@bisresearch.com | www.bisresearch.com
<strong>Research</strong> Scope & BIS Methodology<br />
Key Trends Targeted in the <strong>Report</strong><br />
• What are the emerging trends in the global molecular diagnostics market? How are these trends revolutionizing the<br />
diagnostic procedure?<br />
• Which technologies are anticipated to break-through the current molecular diagnostic regime?<br />
• Which companies are anticipated to be highly disruptive in the future and why?<br />
• What are the regulatory procedures that are required to unify the approval process for emerging molecular<br />
diagnostics? How will these enhance the reimbursement scenario?<br />
• What are the gaps in regularizing optimum molecular diagnostic adoption in regular healthcare routines? How are<br />
these gaps being tackled?<br />
1. Scope of the <strong>Report</strong><br />
The report constitutes of an in-depth study of the global molecular diagnostics market, including a thorough analysis<br />
of the types of products. The study also presents a detailed analysis of the market dynamics and the estimation of<br />
the market size over the forecast period 2018-2028. The scope of this report is focused on the molecular diagnostics<br />
products for different applications, for different end-users, and their country-wise analysis. The market value may vary<br />
from 5-7% as the data has been collected from different sources at the regional and country level.<br />
The market analysis includes an in-depth examination of the key ecosystem players and key strategies and developments<br />
taking place in this market. However, the market estimation only includes the molecular diagnostics manufacturers<br />
across the globe. Further, it includes the market dynamics (market drivers, challenges, and opportunities) and industry<br />
analysis. The purpose of the study is to gain a holistic view of the global molecular diagnostics market in terms of<br />
various factors influencing it, including regulatory reforms, and technological advancements. The market has been<br />
segmented into ‘products’, ‘applications’, ‘technologies’, ‘end-users’, and ‘regions’. The scope of this report is centered<br />
upon conducting a detailed study of the products allied with the molecular diagnostics market. In addition, the study<br />
also includes the exhaustive information on the unmet needs, perception on the new products, competitive landscape,<br />
market share of leading manufacturers, growth potential of each product, application, region, and company, as well as<br />
other vital information with respect to global molecular diagnostics market.<br />
Products, for which no real-time data was available in the public domain, personnel from the respective companies were<br />
contacted in order to gain valuable information pertaining to the product in different regions and their corresponding<br />
prices. This information was then used to estimate the global number for a particular product which was later validated<br />
by the industry experts.<br />
2. <strong>Market</strong> <strong>Research</strong> Methodology<br />
The research methodology design adopted for this specific study includes a mix of data collected from primary and<br />
secondary sources. Both primary sources (in-house experts, industry leaders, and market players) and secondary<br />
sources (a host of paid and unpaid databases) along with analytical tools have been used exhaustively to build the<br />
forecast and predictive models.<br />
sales@bisresearch.com | www.bisresearch.com
<strong>Research</strong> Scope & BIS Methodology<br />
Figure 1: <strong>Research</strong> Methodology<br />
Scope Definition<br />
<strong>Research</strong> Design<br />
<strong>Market</strong> Study<br />
Qualitative<br />
Quantitative<br />
Primary Interviews/<br />
Secondary <strong>Research</strong><br />
Top Down and<br />
Bottom Up<br />
Primary &<br />
Secondary Data<br />
<strong>Report</strong><br />
Writing<br />
Data Validation<br />
Data Analysis<br />
Data Collection<br />
Source: BIS <strong>Research</strong> Analysis.<br />
Primary Data Sources<br />
The key data points taken from the primary sources include:<br />
• Validation and triangulation of all the numbers and graphs<br />
• Validation of report segmentation and key qualitative findings<br />
• Understanding the competitive landscape<br />
• Understanding and considering the factors for market dynamics of various market segments and sub-segments<br />
• Validation of impact analysis of macro and micro factors in different countries<br />
• Percentage split of individual markets for geographical analysis<br />
sales@bisresearch.com | www.bisresearch.com
<strong>Research</strong> Scope & BIS Methodology<br />
Secondary Data Sources<br />
The research study involves the usage of extensive secondary sources such as databases, company websites, and<br />
annual reports, among others.<br />
The following figure exhibits key secondary data sources considered in this report:<br />
Figure 2: Secondary Data Sources<br />
Stock Analyst Websites<br />
• Seeking Alpha<br />
• Yahoo Finance<br />
• Wiki Finance<br />
• The Wall Street Journal<br />
Company Sources<br />
• Annual <strong>Report</strong>s<br />
• Press Releases<br />
• Sec Filings<br />
• Investor Presentations<br />
• Financial Disclosures<br />
SECONDARY DATA<br />
SOURCES<br />
Government and Regulatory Sources<br />
• Centers for Disease Control and<br />
Prevention (CDC)<br />
• The World Health Organization<br />
(WHO)<br />
• The National Health Services (NHS)<br />
• The National Center for<br />
Biotechnology Infromation (NCBI)<br />
• The Food & Drug Administration of<br />
United States (U.S. FDA)<br />
Public and Private Database<br />
• Medline<br />
• PubMed<br />
• National Library of Medicine<br />
• ProQuest<br />
• CMS Database<br />
• Medicare Beneficiary Database<br />
• Oxon Epidemiology<br />
Source: BIS <strong>Research</strong> Analysis.<br />
The key data points taken from the secondary sources include:<br />
• Segmentation breakups, split-ups, and percentage shares<br />
• Data for market value<br />
• Key industry trends of the top players of the market<br />
• Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation<br />
• Quantitative data for mathematical and statistical calculations<br />
sales@bisresearch.com | www.bisresearch.com
<strong>Research</strong> Scope & BIS Methodology<br />
Figure 3: Data Triangulation<br />
List of Tables<br />
The following figure exhibits data triangulation considered in this study:<br />
Data Analysis<br />
The data collected from Primary and Secondary<br />
resources is validated and analyzed to arrive at<br />
a market size through a top-down or a bottomup<br />
approach.<br />
Bis <strong>Research</strong><br />
Internal Repository<br />
Primary Sources<br />
DATA<br />
TRIANGULATION<br />
Secondary Sources<br />
Primary Sources<br />
Secondary Sources<br />
Qualitative and Quantitative data collected from<br />
interviews conducted with senior management<br />
personnel from renowned companies and<br />
industry experts.<br />
Qualitative data collected from reliable<br />
resources, white papers, e-magazines,<br />
government records, and trade data.<br />
Source: BIS <strong>Research</strong> Analysis.<br />
REQUEST FOR SAMPLE<br />
sales@bisresearch.com | www.bisresearch.com
BIS <strong>Research</strong><br />
39111 Paseo Padre PKWY STE 313,<br />
Fremont CA 94538-1686,<br />
Tel: +1-510-404-8135<br />
Global Delivery Centre<br />
Tapasya Corp Heights, Subarea,<br />
Sector 126, Noida, NCR-201303 India<br />
Tel: +91 120 4261540 / +91 120 4261544<br />
To know more about us, please visit our website:<br />
bisresearch.com<br />
For other queries contact:<br />
sales@bisresearch.com<br />
sales@bisresearch.com sales@bisresearch.com | | www.bisresearch.com
Change language